Modality
Vaccine
MOA
AHRant
Target
MET
Pathway
Checkpoint
Melanoma
Development Pipeline
Preclinical
~Sep 2023
→ ~Dec 2024
Phase 1
Mar 2025
→ Feb 2025
Phase 1Current
NCT04883224
466 pts·Melanoma
2025-03→2025-02·Terminated
466 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-101.1y agoInterim· Melanoma
Trial Timeline
P1
Termina…
Catalysts
Interim
2025-02-10 · 1.1y ago
Melanoma
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04883224 | Phase 1 | Melanoma | Terminated | 466 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| RAP-2478 | Rapport Ther | Phase 3 | MET |